Shinya Fukunishi

Shinya Fukunishi

Auto-generated profile, based on publicly available information

Shinya Fukunishi

Department of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
YSYoshio Sakai
Yoshio Sakai
SFShinya Fukunishi
Shinya Fukunishi
MTMasayuki Takamura
Masayuki Takamura
OIOto Inoue
Oto Inoue
STShinichiro Takashima
Shinichiro Takashima
SKShuichi Kaneko
Shuichi Kaneko
Background: Liver cirrhosis results from chronic hepatitis, and is characterized by advanced fibrosis due to long-term hepatic inflammation. Cirrhosis ultimately leads to manifestations of jaundice, ascites, and encephalopathy, and increases the risk of hepatocellular carcinoma. Once cirrhosis is established, resulting in hepatic failure, no effective treatment is available. Therefore, novel therapies to inhibit disease progression of cirrhosis are needed. Objective: The objective of this investigator-initiated clinical trial is to assess the safety and efficacy of autologous adipose tissue-derived regenerative (stem) cell therapy delivered to the liver via the hepatic artery in patients with liver cirrhosis. Methods: Through consultation with the Japan Pharmaceuticals and Medical Devices Agency, we designed a clinical trial to assess a therapy for liver cirrhosis based on autologous adipose tissue-derived regenerative (stem) cells, which are extracted using an adipose tissue dissociation device. The primary endpoints of the trial are the serum albumin concentration, prothrombin activity, harmful events, and device malfunction. Results: Enrollment and registration were initiated in November 2017, and the follow-up period ended in November 2019. Data analysis and the clinical study report will be completed by the end of March 2020. Conclusions: Completion of this clinical trial, including data analysis, will provide data on the safety and efficacy of this novel liver repair therapy based on autologous adipose tissue-derived regenerative (stem) cells using an adipose tissue dissociation device. Trial Registration: UMIN Clinical Trials Registry UMIN000022601; https://tinyurl.com/w9uqw3q International Registered Report Identifier (IRRID): DERR1-10.2196/17904

14 June 2025 in Hepatology Research
Verified
Journal Article
Closed access
TMTomomitsu Matono
Tomomitsu Matono
Toshifumi TadaToshifumi Tada
Toshifumi Tada
HTHidenori Toyoda
Hidenori Toyoda
AHAtsushi Hiraoka
Atsushi Hiraoka
MHMasashi Hirooka
Masashi Hirooka
TGthe Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group
the Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group


1 January 2020 in Gastroenterology Review
Verified
Journal Article
Open access
Yoshihiro InoueYoshihiro Inoue
Yoshihiro Inoue
KYKeisuke Yokohama
Keisuke Yokohama
HOHIdeko Ohama
HIdeko Ohama
YTYusuke Tsuchimoto
Yusuke Tsuchimoto
TTTetsuji Terazawa
Tetsuji Terazawa
KUKazuhisa Uchiyama
Kazuhisa Uchiyama
Introduction Laparoscopic hepatectomy (LH) is very difficult to perform in patients with cirrhosis because of the haemor- rhagic and fibrotic nature of the liver, although there are various advantages to laparoscopic surgery. Aim To investigate the surgical outcomes, and efficacy and safety...

25 March 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PDF file
TOTakeshi Ogura
Takeshi Ogura
DMDaisuke Masuda
Daisuke Masuda
TTToshihisa Takeuchi
Toshihisa Takeuchi
SFShinya Fukunishi
Shinya Fukunishi
KHKazuhide Higuchi
Kazuhide Higuchi

6 September 2025 in Hepatology Research
Verified
Journal Article
Closed access
THTakeshi Hatanaka
Takeshi Hatanaka
YYYutaka Yata
Yutaka Yata
AHAtsushi Hiraoka
Atsushi Hiraoka
Toshifumi TadaToshifumi Tada
Toshifumi Tada
MHMasashi Hirooka
Masashi Hirooka
RJReal‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)